Summary Routine newborn screening is necessary for the effective diagnosis of galactosemia. The criticism that routine screening for galactosemia is unnecessary is based on the misconception that the diagnosis will almost always be made clinically, since the disease produces clinical manifestations in the infant. Acutally most newborn infants, detected by routine screening, were not suspected to have galactosemia, even when ill. Furthermore, some infants with clinically important transferase variants are not ill as neonates. In Massachusetts, a black infant who probably has the Negro variant form of galactosemia and an infant with the Rennes variant of galactosemia 6 were clinically normal at five days of age when detected by routine screening. Complications of galactosemia can occur in both variants if treatment is not given. In addition, galactokinase deficiency, which results in cataracts but not in acute illness, 32 cannot be detected on a clinical basis until the cataracts have become apparent, when it is too late for preventive therapy. The full impact of galactosemia on the newborn infant has become evident only since routine newborn screening has been initiated. It is now apparent that death associated with bacterial sepsis may occur in about 30% of those with untreated classical galactosemia. 4 In most of these deaths diagnosis and treatment were delayed until the second week of life. Consequently, screening for galactosemia should be performed on a blood specimen that is obtained no later than the third or fourth day of life and is delivered promptly to the screening laboratory. There should be sufficient medical back-up available to the laboratory so that the attending physician can be quickly contacted by telephone when an abnormality suggesting galactosemia is encountered. Further procedures should follow: (1) Urine should be tested for reducing substance. (2) If urinary reducing substance is present, galactosemia should be presumed; milk feedings should be discontinued; and blood and urine specimens should be sent to a laboratory for confirmatory testing. (3) If the infant is ill, bacterial cultures should be obtained and treatment for sepsis initiated. (4) If galactosemia is confirmed, treatment should be continued. Otherwise, treatment can be discontinued. Galactosemia screening should be routine for all newborn infants. It is a disorder with definite and severe complications, but one in which the complications can be prevented with simple and inexpensive treatment. When a test for galactose and gal-l-P, such as the Paigen assay, is also applied to the newborn blood specimen that is, submitted for PKU screening, galactosemia can be detected efficiently and effectively.